



## Verona Pharma plc

Current share price 16.75p  
 Market cap £36.63m  
 Number of Shares 215.48m  
 Ticker VRP

**Broker/Nomad**  
 Evolution Securities Limited

**Financial PR**  
 Bishopsgate Communications

### Recent Announcements

11 Sept 09	RPL554 Proven Safe & Effective in Asthma Patients
11 Sept 09	Board Appointment
04 Sept 09	Half Yearly Report
02 Sept 09	Change of Nomad
29 May 09	Total Voting Rights
22 May 09	Result of AGM
20 May 09	Clinical Trial Update
11 May 09	Issue of Equity

### Key Personnel

Professor Clive Page - Chairman  
 Professor Michael Walker - CEO  
 Lui Franciosi - COO  
 Danny Lowe - CFO  
 Claire Poll - Corporate Director  
 Trevor Jones - Non-Exec. Director  
 Stuart Bottomley - Non-Exec. Director  
 Dr Patrick Humphrey - Non-Exec. Director

### Share Price Chart



### Contact Details

Verona Pharma Plc  
 Suite 21 - Alpha House  
 100 Borough High Street  
 London SE1 1LB  
 Tel: +44 (0)20 7863 3300  
 Fax: +44 (0)20 7863 3314

### Media Enquiries:

Bishopsgate Communications Ltd  
 E: veronapharma@bishopsgatecommunications.com

T: 020 7562 3350

## Overview

Verona Pharma plc ('VRP') is a life sciences company dedicated to the research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hayfever) and chronic obstructive pulmonary disease (COPD) (smokers' disease), as well as chronic inflammatory diseases.

On 19 September 2006, Verona Pharma plc changed its name from Isis Resources plc ('Isis') after it successfully acquired the entire issued share capital of Rhinopharma Limited, a drug discovery company founded in Vancouver, Canada. Isis was incorporated on 24 February 2005 in England and Wales, and was admitted to trading on AIM on 23 March 2005.

## Current and recent activity

The Company has three drug treatments under development aimed at the respiratory and inflammatory diseases markets:

**RPL554:** Successful completion Phase I/IIa clinical trial. RPL554 is a new treatment for asthma which works by relaxing airways (bronchodilation) and reducing inflammation. The drug, which originates from the creative mind of Sir David Jack, is a potential replacement for current asthma therapies.

Trial results demonstrate that RPL554 has beneficial actions in asthmatics, and potentially in patients with allergic rhinitis. The Company is currently engaged in discussions to license the drug to third parties.

**NAIPs:** Novel anti-inflammatory drugs based upon molecules from biological sources - using natural sugars from marine creatures to combat inflammation.

**Cough:** New ways to treat cough - a major unmet medical need. The Company is working on a new approach to address this neglected condition.

**11 Sept 2009:** Appointment of Dr Patrick P. A. Humphrey, B.Pharm. Hons, Ph.D, D.Sc, OBE, as Non-Executive Director.

## Outlook

**R&D Pipeline for Continued Growth:** Leverage the experience and network of the Company's board and management team to build a pipeline of new potential drug candidates for the treatment of respiratory and inflammatory diseases.

**Targeting significant markets:** Focus on markets that offer significant potential. There is currently no ideal drug treatment for asthma, rhinitis and COPD; each disease represents a multi-million dollar market.

**Rapid Route to Market:** Pursue drug development programmes with a relatively rapid and low cost route to market, such as allergic rhinitis.

**Early Crucial Milestones:** Define early crucial milestones for the Company's programmes so that any scientific or other issues can be identified before a significant investment is made.

**Virtual R&D Model:** Outsource much of the Company's research and development, thereby reducing the need for a large specialized workforce and investment in physical infrastructure.

**Commercialization through strategic partnerships and business associations:** Enter into outlicensing or other arrangements with commercial development partners at the clinical proof of concept or earlier, with the intention of accelerating commercialization and increasing the chances of success.

For more information about the company and its projects, please view Prof. Michael Walker's 'Trading Places' interview done on 20. Feb. 2009, located at: <http://www.veronapharma.com/s/Home.asp>